Nina Vibeche Skei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nina Vibeche Skei has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Lise Tuset Gustad
Faculty of Nursing and Health Sciences, Nord University
16 shared publications - Erik Solligård
Mid-Norway Sepsis Research Group, Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway
12 shared publications - Anne-Sofie Furberg
Faculty of Health and Social Sciences, Molde University College , 6410 Molde
7 shared publications - Hanne Frydenberg
Department of Oncology, Oslo University Hospital, Oslo, Norway
7 shared publications - Inger Thune
Department of Oncology, Oslo University Hospital, Oslo, Norway
7 shared publications - Marit Husby
Faculty of Health and Social Sciences, Molde University College, Molde, Norway
7 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Supplementary Figure 1 shows flowchart of the study population.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Supplementary Figure 1 shows flowchart of the study population.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Background:Patients with cancer who had sepsis experience a higher mortality risk than noncancer patients. However, it remains unclear how this risk varies with cancer type and metastasis status, sex, age, and infecting microbe.Methods:This nationwide cohort study included all noncancer patients and those with cancer ≥18 years hospitalized with sepsis in Norway from 2008 to 2021. Cancer status, sepsis, and hospital mortality were identified from the Norwegian Patient Registry (International Classification of Diseases 10th revision codes). Multivariable regression analyses estimated absolute and relative risks (RR) of hospital mortality across subgroups.Results:Of 222,832 hospitalized patients with sepsis, 37,692 (16.9%) had cancer. Hospital mortality was higher in patients with cancer, at 16.9% (males) and 16.2% (females) with nonmetastatic disease, and at 27.1% (males) and 26.2% (females) with metastatic disease. Compared with noncancer patients, adjusted RRs (95% confidence interval) of hospital death were 1.39 (1.34–1.44, males) and 1.63 (1.55–1.71, females) for nonmetastatic cancer and 2.27 (2.18–2.37, males) and 2.75 (2.62–2.89, females) for metastatic cancer. The type of cancer was a key prognostic factor. The association between cancer and mortality was strongest in metastatic patients below 50 years [males 40–49 years: RR, 5.94 (4.43–7.97); females 18–39 years: RR, 8.28 (5.12–13.37)] and in those with gram-negative sepsis.Conclusions:The increased hospital mortality in patients with cancer varied with cancer type and the presence of metastasis. The association between cancer and mortality was strongest in females and young adults, as well as in gram-negative sepsis.Impact:Knowledge of the specific aspects of sepsis in patients with cancer may improve cancer care and guide future research on targeted sepsis therapies.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Background:Patients with cancer who had sepsis experience a higher mortality risk than noncancer patients. However, it remains unclear how this risk varies with cancer type and metastasis status, sex, age, and infecting microbe.Methods:This nationwide cohort study included all noncancer patients and those with cancer ≥18 years hospitalized with sepsis in Norway from 2008 to 2021. Cancer status, sepsis, and hospital mortality were identified from the Norwegian Patient Registry (International Classification of Diseases 10th revision codes). Multivariable regression analyses estimated absolute and relative risks (RR) of hospital mortality across subgroups.Results:Of 222,832 hospitalized patients with sepsis, 37,692 (16.9%) had cancer. Hospital mortality was higher in patients with cancer, at 16.9% (males) and 16.2% (females) with nonmetastatic disease, and at 27.1% (males) and 26.2% (females) with metastatic disease. Compared with noncancer patients, adjusted RRs (95% confidence interval) of hospital death were 1.39 (1.34–1.44, males) and 1.63 (1.55–1.71, females) for nonmetastatic cancer and 2.27 (2.18–2.37, males) and 2.75 (2.62–2.89, females) for metastatic cancer. The type of cancer was a key prognostic factor. The association between cancer and mortality was strongest in metastatic patients below 50 years [males 40–49 years: RR, 5.94 (4.43–7.97); females 18–39 years: RR, 8.28 (5.12–13.37)] and in those with gram-negative sepsis.Conclusions:The increased hospital mortality in patients with cancer varied with cancer type and the presence of metastasis. The association between cancer and mortality was strongest in females and young adults, as well as in gram-negative sepsis.Impact:Knowledge of the specific aspects of sepsis in patients with cancer may improve cancer care and guide future research on targeted sepsis therapies.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Supplementary Table S3 shows Distribution of cancer patients with neutropenia and Absolute Risks (AR) (95% CI) and Relative Risks (RR) (95% CI) of hospital mortality by sex and the presence of neutropenia. Norwegian hospitals, 2008 to 2021.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Supplementary Table S3 shows Distribution of cancer patients with neutropenia and Absolute Risks (AR) (95% CI) and Relative Risks (RR) (95% CI) of hospital mortality by sex and the presence of neutropenia. Norwegian hospitals, 2008 to 2021.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Supplementary Methods shows ICD-10 codes used to define sepsis, cancer, and comorbidity.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Supplementary Methods shows ICD-10 codes used to define sepsis, cancer, and comorbidity.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Supplementary Table S1 shows Hospital mortality in cancer patients with sepsis by cancer subtype, Norwegian hospitals 2008 to 2021.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Supplementary Table S1 shows Hospital mortality in cancer patients with sepsis by cancer subtype, Norwegian hospitals 2008 to 2021.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S2A and S2B from Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Supplementary Table S2A shows Hospital mortality in male cancer patients with sepsis by cancer subtype and metastatic status, Norwegian hospitals 2008 to 2021.Supplementary Table S2B shows Hospital mortality in female cancer patients with sepsis by cancer subtype and metastatic status, Norwegian hospitals 2008 to 2021.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S2A and S2B from Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Supplementary Table S2A shows Hospital mortality in male cancer patients with sepsis by cancer subtype and metastatic status, Norwegian hospitals 2008 to 2021.Supplementary Table S2B shows Hospital mortality in female cancer patients with sepsis by cancer subtype and metastatic status, Norwegian hospitals 2008 to 2021.
- Open Access
- 22 April 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Long-term trends in incidence and mortality in Staphylococcus aureus bacteraemia; a retrospective population-based study from Central Norway 1996–2022
Objectives: This study aims to examine changes in incidence and mortality in Staphylococcus aureus bacteraemia (SAB) over time and between sexes, describe clinical characteristics and asses their associations with 30-day mortality. Methods: We included 837 first-time SAB episodes from 1996 to 2022 in patients aged 18 years or older recorded in the Nord-Trøndelag Hospital Trust Sepsis Registry. Logistic regression was used to investigate time trends and associations with mortality. The study period was divided into early- (1996–2004), mid- (2005–2013) and late- (2014–2022) periods, and results are reported for each period and overall. Results: The incidence of SAB increased from 20.0 to 40.3 per 100 000 person years from the early- to the late periods, with males accounting for 522 (62.4%) of all cases. Mortality decreased from 22.6% to 19.0% in males and 29.2% to 20.0% in females. Higher age, malignancy, congestive heart failure, pulmonary infection focus, and unknown focus were associated with increased 30-days mortality. Conclusion: The incidence rate of SAB increased significantly from 1996 to 2022, with a consistently higher rate in males compared to females. While the highest mortality rate was observed in females in the earliest period, the mortality rate was similar between the sexes in the last period. The decline in mortality occurred despite an ageing patient population and a stable burden of comorbidities. With the exception of age, none of the variables associated with increased or decreased mortality changed significantly over time. Clinical trial number: Not applicable.
- 22 April 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessLong-term trends in incidence and mortality in Staphylococcus aureus bacteraemia; a retrospective population-based study from Central Norway 1996–2022
Objectives: This study aims to examine changes in incidence and mortality in Staphylococcus aureus bacteraemia (SAB) over time and between sexes, describe clinical characteristics and asses their associations with 30-day mortality. Methods: We included 837 first-time SAB episodes from 1996 to 2022 in patients aged 18 years or older recorded in the Nord-Trøndelag Hospital Trust Sepsis Registry. Logistic regression was used to investigate time trends and associations with mortality. The study period was divided into early- (1996–2004), mid- (2005–2013) and late- (2014–2022) periods, and results are reported for each period and overall. Results: The incidence of SAB increased from 20.0 to 40.3 per 100 000 person years from the early- to the late periods, with males accounting for 522 (62.4%) of all cases. Mortality decreased from 22.6% to 19.0% in males and 29.2% to 20.0% in females. Higher age, malignancy, congestive heart failure, pulmonary infection focus, and unknown focus were associated with increased 30-days mortality. Conclusion: The incidence rate of SAB increased significantly from 1996 to 2022, with a consistently higher rate in males compared to females. While the highest mortality rate was observed in females in the earliest period, the mortality rate was similar between the sexes in the last period. The decline in mortality occurred despite an ageing patient population and a stable burden of comorbidities. With the exception of age, none of the variables associated with increased or decreased mortality changed significantly over time. Clinical trial number: Not applicable.
- Open Access
- 4 December 2025
- Published by Springer Nature in Research Square
Long-term trends in incidence and mortality in Staphylococcus aureus bacteraemia; a retrospective population-based study from Central Norway 1996-2022
Objectives This study aims to examine changes in incidence and mortality in Staphylococcus aureus bacteraemia (SAB) over time and between sexes, describe clinical characteristics and assess their associations with 30-day mortality. Methods We included 837 first-time SAB episodes from 1996 through 2022 in patients aged 18 years or older recorded in the Nord-Trøndelag Hospital Trust Sepsis Registry. Logistic regression was used to investigate time trends and associations with mortality. The study period was divided into early- (1996–2004), mid- (2005–2013) and late- (2014–2022) periods, and results are reported for each period and overall. Results The incidence of SAB increased from 20.0 to 40.3 per 100 000 person years from the early- to the late periods, with males accounting for 522 (62.4%) of all cases. Mortality decreased from 22.6% to 19.0% in males and 29.2% to 20.0% in females. Higher age, malignancy, congestive heart failure, pulmonary infection focus, and unknown focus were associated with increased 30-days mortality. Conclusion The incidence rate of SAB increased significantly from 1996 to 2022, with a consistently higher rate in males compared to females. While the highest mortality rate was observed in females in the earliest period, the mortality rate declined more in females than males, resulting in similar rates between the sexes in the last period. This decline occurred despite an ageing patient population and a stable burden of comorbidities. With the exception of age, none of the variables associated with increased or decreased mortality changed significantly over time.
- 4 December 2025
- Published by Springer Nature in Research Square
Open AccessLong-term trends in incidence and mortality in Staphylococcus aureus bacteraemia; a retrospective population-based study from Central Norway 1996-2022
Objectives This study aims to examine changes in incidence and mortality in Staphylococcus aureus bacteraemia (SAB) over time and between sexes, describe clinical characteristics and assess their associations with 30-day mortality. Methods We included 837 first-time SAB episodes from 1996 through 2022 in patients aged 18 years or older recorded in the Nord-Trøndelag Hospital Trust Sepsis Registry. Logistic regression was used to investigate time trends and associations with mortality. The study period was divided into early- (1996–2004), mid- (2005–2013) and late- (2014–2022) periods, and results are reported for each period and overall. Results The incidence of SAB increased from 20.0 to 40.3 per 100 000 person years from the early- to the late periods, with males accounting for 522 (62.4%) of all cases. Mortality decreased from 22.6% to 19.0% in males and 29.2% to 20.0% in females. Higher age, malignancy, congestive heart failure, pulmonary infection focus, and unknown focus were associated with increased 30-days mortality. Conclusion The incidence rate of SAB increased significantly from 1996 to 2022, with a consistently higher rate in males compared to females. While the highest mortality rate was observed in females in the earliest period, the mortality rate declined more in females than males, resulting in similar rates between the sexes in the last period. This decline occurred despite an ageing patient population and a stable burden of comorbidities. With the exception of age, none of the variables associated with increased or decreased mortality changed significantly over time.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (2) , 264-275
Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Background: Patients with cancer who had sepsis experience a higher mortality risk than noncancer patients. However, it remains unclear how this risk varies with cancer type and metastasis status, sex, age, and infecting microbe. Methods: This nationwide cohort study included all noncancer patients and those with cancer ≥18 years hospitalized with sepsis in Norway from 2008 to 2021. Cancer status, sepsis, and hospital mortality were identified from the Norwegian Patient Registry (International Classification of Diseases 10th revision codes). Multivariable regression analyses estimated absolute and relative risks (RR) of hospital mortality across subgroups. Results: Of 222,832 hospitalized patients with sepsis, 37,692 (16.9%) had cancer. Hospital mortality was higher in patients with cancer, at 16.9% (males) and 16.2% (females) with nonmetastatic disease, and at 27.1% (males) and 26.2% (females) with metastatic disease. Compared with noncancer patients, adjusted RRs (95% confidence interval) of hospital death were 1.39 (1.34–1.44, males) and 1.63 (1.55–1.71, females) for nonmetastatic cancer and 2.27 (2.18–2.37, males) and 2.75 (2.62–2.89, females) for metastatic cancer. The type of cancer was a key prognostic factor. The association between cancer and mortality was strongest in metastatic patients below 50 years [males 40–49 years: RR, 5.94 (4.43–7.97); females 18–39 years: RR, 8.28 (5.12–13.37)] and in those with gram-negative sepsis. Conclusions: The increased hospital mortality in patients with cancer varied with cancer type and the presence of metastasis. The association between cancer and mortality was strongest in females and young adults, as well as in gram-negative sepsis. Impact: Knowledge of the specific aspects of sepsis in patients with cancer may improve cancer care and guide future research on targeted sepsis therapies.
- 1 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (2) , 264-275
Open AccessCancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Background: Patients with cancer who had sepsis experience a higher mortality risk than noncancer patients. However, it remains unclear how this risk varies with cancer type and metastasis status, sex, age, and infecting microbe. Methods: This nationwide cohort study included all noncancer patients and those with cancer ≥18 years hospitalized with sepsis in Norway from 2008 to 2021. Cancer status, sepsis, and hospital mortality were identified from the Norwegian Patient Registry (International Classification of Diseases 10th revision codes). Multivariable regression analyses estimated absolute and relative risks (RR) of hospital mortality across subgroups. Results: Of 222,832 hospitalized patients with sepsis, 37,692 (16.9%) had cancer. Hospital mortality was higher in patients with cancer, at 16.9% (males) and 16.2% (females) with nonmetastatic disease, and at 27.1% (males) and 26.2% (females) with metastatic disease. Compared with noncancer patients, adjusted RRs (95% confidence interval) of hospital death were 1.39 (1.34–1.44, males) and 1.63 (1.55–1.71, females) for nonmetastatic cancer and 2.27 (2.18–2.37, males) and 2.75 (2.62–2.89, females) for metastatic cancer. The type of cancer was a key prognostic factor. The association between cancer and mortality was strongest in metastatic patients below 50 years [males 40–49 years: RR, 5.94 (4.43–7.97); females 18–39 years: RR, 8.28 (5.12–13.37)] and in those with gram-negative sepsis. Conclusions: The increased hospital mortality in patients with cancer varied with cancer type and the presence of metastasis. The association between cancer and mortality was strongest in females and young adults, as well as in gram-negative sepsis. Impact: Knowledge of the specific aspects of sepsis in patients with cancer may improve cancer care and guide future research on targeted sepsis therapies.
- Open Access
- 19 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0320054
Number of ICD-10 diagnosis fields required to capture sepsis in administrative data and truncation bias: A nationwide prospective registry study
Background: In observational studies that use administrative data, it is essential to report technical details such as the number of International Classification of Disease (ICD) coding fields extracted. This information is crucial for ensuring comparability between studies and for avoiding truncation bias in estimates, particularly for complex conditions like sepsis. Specific sepsis codes (explicit sepsis) are suggested to be identified by extracting 15 diagnosis fields, while for implicit sepsis, which comprises an infection code combined with acute organ failure, the number of diagnosis field remains unknown. Objective: The objective was to explore the necessary number of diagnosis fields to capture explicit and implicit sepsis. Materials and methods: We conducted a study utilizing The Norwegian Patient Register (NPR), which encompasses all medical ICD-10 codes from specialized health services in Norway. Data were extracted for all adult patients with hospital discharges registered with explicit and implicit sepsis codes from all Norwegian hospitals between 2008 through 2021. Results: Out of 317,705 sepsis admissions, we identified 105,499 ICD-10 codes for explicit sepsis, while implicit sepsis was identified through 270,346 codes for infection in combination with 240,789 codes for acute organ failure. Through our analysis, we found that 55%, 37%, and 10% of the explicit, infection, and acute organ failure codes, respectively, were documented as the main diagnosis. The proportion of explicit and infection codes peaked in the primary diagnosis field, while for acute organ failure codes, this was true in the third secondary diagnosis field. Notably, the cumulative proportion reached 99% in diagnosis field 10 for explicit codes and in diagnosis field 13 for implicit codes. Conclusion: Expanding the utilization of multiple diagnosis fields can enhance the comparability of data in epidemiological studies, both internationally and within countries. To make truncation bias visible, reporting guidelines should specify the number of diagnosis fields when extracting ICD-10 codes.
- 19 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0320054
Open AccessNumber of ICD-10 diagnosis fields required to capture sepsis in administrative data and truncation bias: A nationwide prospective registry study
Background: In observational studies that use administrative data, it is essential to report technical details such as the number of International Classification of Disease (ICD) coding fields extracted. This information is crucial for ensuring comparability between studies and for avoiding truncation bias in estimates, particularly for complex conditions like sepsis. Specific sepsis codes (explicit sepsis) are suggested to be identified by extracting 15 diagnosis fields, while for implicit sepsis, which comprises an infection code combined with acute organ failure, the number of diagnosis field remains unknown. Objective: The objective was to explore the necessary number of diagnosis fields to capture explicit and implicit sepsis. Materials and methods: We conducted a study utilizing The Norwegian Patient Register (NPR), which encompasses all medical ICD-10 codes from specialized health services in Norway. Data were extracted for all adult patients with hospital discharges registered with explicit and implicit sepsis codes from all Norwegian hospitals between 2008 through 2021. Results: Out of 317,705 sepsis admissions, we identified 105,499 ICD-10 codes for explicit sepsis, while implicit sepsis was identified through 270,346 codes for infection in combination with 240,789 codes for acute organ failure. Through our analysis, we found that 55%, 37%, and 10% of the explicit, infection, and acute organ failure codes, respectively, were documented as the main diagnosis. The proportion of explicit and infection codes peaked in the primary diagnosis field, while for acute organ failure codes, this was true in the third secondary diagnosis field. Notably, the cumulative proportion reached 99% in diagnosis field 10 for explicit codes and in diagnosis field 13 for implicit codes. Conclusion: Expanding the utilization of multiple diagnosis fields can enhance the comparability of data in epidemiological studies, both internationally and within countries. To make truncation bias visible, reporting guidelines should specify the number of diagnosis fields when extracting ICD-10 codes.